The body of real-world evidence around Covid-19 continues to build, and a study released Aug. 26 in The Lancet points to concerning long-term effects for hospital survivors at the one-year mark.
The National Institutes of Health (NIH) is testing a booster shot of Covid-19 vaccines in people with autoimmune diseases who have not responded well to the primary vaccine course.
The number of coronavirus patients in U.S. hospitals breached 100,000, the highest level in eight months, according to the Department of Health and Human Services, as a resurgence of Covid-19 spurred by the highly contagious Delta variant strains the nation’s health care system.
Half of children aged 12 to 17 have received at least their first vaccination dose against Covid-19, and that age group has the fastest growth rate in vaccinations, the White House said on Aug. 27.
U.S. companies are scrambling to boost production of coronavirus tests increasingly in short supply as Covid-19 cases soar and schools and employers revive surveillance programs that will require tens of millions of tests, according to industry executives and state health officials.
Researchers at the National Autonomous University of Mexico (UNAM) created a facemask using silver and copper nanolayers that neutralizes SARS-CoV-2, the virus that causes Covid-19, the university’s official gazette said on Aug. 26.
Illinois will require all eligible students and school employees to be vaccinated and re-instituted an indoor mask mandate under an order announced by Governor J.B. Pritzker on Aug. 26.
Pfizer Inc. on Aug. 25 said a booster dose of the company’s two-shot Covid-19 vaccine spurs a more than threefold increase in antibodies against the coronavirus, as the drugmaker seeks U.S. regulatory approval for a third injection.
The use of Pfizer Inc. and German partner BioNTech SE’s widely used Covid-19 vaccine marginally increases the risk of heart inflammation, but the risk is higher among those infected with the coronavirus, a study published on Aug. 25 in the New England Journal of Medicine showed.
U.S. health regulators could approve a third Covid-19 shot for adults beginning at least six months after full vaccination, instead of the previously announced eight-month gap, the Wall Street Journal reported on Aug. 25.
